<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00816907</url>
  </required_header>
  <id_info>
    <org_study_id>N01 MH090001-03</org_study_id>
    <secondary_id>N01MH90001 DSIR AT</secondary_id>
    <nct_id>NCT00816907</nct_id>
  </id_info>
  <brief_title>The Use of Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (The METS Study)</brief_title>
  <acronym>METS</acronym>
  <official_title>Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (METS) - Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Mental Health (NIMH)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the usefulness of the medication metformin in treating people with
      schizophrenia or schizoaffective disorder who are overweight and also taking antipsychotic
      medications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Schizophrenia is a chronic mental disorder that is characterized, in part, by psychotic
      symptoms. Psychotic symptoms include hallucinations and delusions, in which a person has
      abnormal experiences or beliefs, and are commonly treated with antipsychotic medications.
      Unfortunately, a side effect of many antipsychotics is unwanted weight gain, which can lead
      to physical illness. Use of the drug metformin has resulted in weight loss among diabetics.
      Metformin has also been shown to cause weight loss in preliminary studies of people taking
      atypical antipsychoticsâ€”a newer, second generation of antipsychotic medications. Metformin is
      currently approved by the Food and Drug Administration to treat only people with diabetes.
      This study will test the usefulness of prescribing metformin as a second medication to treat
      people with schizophrenia or schizoaffective disorder who are overweight and taking
      antipsychotics. The study will also provide important feasibility information for future
      larger studies.

      Participation in this study will last 16 weeks. After undergoing baseline assessments,
      participants will be randomly assigned to receive either metformin or placebo, both of which
      will be taken twice daily for the duration of the study. All participants will also receive
      behavioral therapy that will teach them about reducing their weight through diet and
      exercise. Participants will undergo assessments at 11 study visits: the first 2 will include
      screening and baseline testing, the next 2 visits will take place after the first and second
      weeks of receiving treatment, and the last 7 visits will take place every 2 weeks until the
      end of the study. Assessments will include measurements of body weight, waist-to-hip ratio,
      and vital signs; clinical interviews about medication adherence, side effects, and alcohol
      use; and monthly blood tests to assess levels of lipids, glucose, insulin, and hemoglobin
      A1c.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Difference in Body Weight Change Between Participants Assigned to Metformin and Participants Assigned to Placebo</measure>
    <time_frame>Measured at the last study visit</time_frame>
    <description>Mean difference in body weight change between participants assigned to metformin and participants assigned to placebo from baseline to last study visit (up to 16 weeks)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Total Cholesterol From Baseline to 16 Weeks</measure>
    <time_frame>16 weeks</time_frame>
    <description>Total cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HDL Cholesterol From Baseline to 16 Weeks</measure>
    <time_frame>16 weeks</time_frame>
    <description>high-density lipoprotein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in LDL Cholesterol From Baseline to 16 Weeks</measure>
    <time_frame>16 weeks</time_frame>
    <description>low-density lipoprotein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Triglycerides From Baseline to 16 Weeks</measure>
    <time_frame>16 weeks</time_frame>
    <description>serum triglycerides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Glucose From Baseline to 16 Weeks</measure>
    <time_frame>16 weeks</time_frame>
    <description>fasting blood glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Insulin From Baseline to 16 Weeks</measure>
    <time_frame>16 weeks</time_frame>
    <description>Fasting insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hemoglobin A1c From Baseline to 16 Weeks</measure>
    <time_frame>16 weeks</time_frame>
    <description>glycosylated hemoglobin</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">146</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Encapsulated metformin 1000-2000 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo capsules 2-4 daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>500 mg to 1,000 mg taken twice daily for 16 weeks</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 to 2 placebo capsules taken twice daily for 16 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outpatients with a diagnosis of schizophrenia or schizoaffective disorder, as defined
             by DSM-IV-TR criteria and confirmed by the Structured Clinical Interview for DSM-IV
             (SCID)

          -  Duration of illness greater than 1 year, as defined by having initiated antipsychotic
             treatment at least 1 year prior to study entry

          -  Adequate decisional capacity to make a choice about participating in this research
             study

          -  Body mass index (BMI) at or greater than 27

          -  Currently being treated with one or a combination of two antipsychotic medications
             (typical or atypical) and on that drug regimen for at least 2 months prior to study
             entry, with stable dosages for at least 1 month

          -  If taking antidepressants, mood stabilizers, or anxiolytics, the dose must be stable
             for at least 1 month prior to study entry

          -  Willing to use an adequate method of contraception to avoid pregnancy throughout the
             study and for up to 4 weeks after the study. Acceptable methods include oral,
             injectable, or implanted contraceptives; intrauterine devices or barrier methods such
             as condoms; and diaphragms and spermicides.

        Exclusion Criteria:

          -  Inpatient status

          -  Clinical Global Impression Severity (CGI-S) score greater than 6

          -  Currently being treated with more than two antipsychotic medications

          -  Fasting glucose greater than 125

          -  Diagnosis of diabetes mellitus or treatment with insulin or oral hypoglycemics

          -  Previous or current treatment with metformin

          -  Diagnosis of congestive heart failure

          -  Renal impairment, as defined by a serum creatinine level greater than 1.5 in males or
             greater than 1.4 in females, or creatinine estimated glomerular filtration rate (GFR)
             outside of normal limits

          -  Hepatic disease, as defined by aspartate transaminase (AST), alanine transaminase
             (ALT), or c-glutamyl transferase (CGT) greater than 1.5 times upper limit of normal
             (ULN), or total bilirubin greater than 1.2 times ULN

          -  Metabolic acidosis, as defined by serum carbon dioxide less than the lower limit of
             normal

          -  Known hypersensitivity to metformin

          -  Pregnant or breastfeeding

          -  Recent (in the past 30 days) or scheduled radiological studies involving iodinated
             contrast material

          -  Alcohol abuse or dependence within the past month, as determined by the SCID

          -  Other serious and unstable medical condition in the judgment of the investigator

          -  Diagnosis of mental retardation, delirium, or dementia, as defined by DSM-IV-TR

          -  Failed to discontinue 4 weeks prior to study entry any medication used for weight loss

          -  Concurrent treatment with certain drugs that are known to increase metformin blood
             levels should be discussed with the Project Medical Officer.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>L. Fredrik Jarskog, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey A. Lieberman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>T. Scott Stroup, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mental Health Advocates</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Insights</name>
      <address>
        <city>Glen Burnie</city>
        <state>Maryland</state>
        <zip>21061</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Freedom Trail Clinic</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota School of Medicine</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Mexico VA Healthcare System</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Foundation for Mental Hygiene</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Schizophrenia Research</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 2, 2009</study_first_submitted>
  <study_first_submitted_qc>January 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2009</study_first_posted>
  <results_first_submitted>January 3, 2013</results_first_submitted>
  <results_first_submitted_qc>February 13, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 27, 2013</results_first_posted>
  <last_update_submitted>February 13, 2013</last_update_submitted>
  <last_update_submitted_qc>February 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Schizoaffective Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Weight Gain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Antipsychotic Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A randomized, double-blind, placebo-controlled multicenter trial conducted between March 2009 and February 2010 at 17 academic, veterans affairs, and private research clinics. 146 clinically stable overweight outpatients with chronic schizophrenia and schizoaffective disorder were enrolled.</recruitment_details>
      <pre_assignment_details>Prior to randomization prospective participants were screened for eligibility</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Matching over-encapsulated placebo pills</description>
        </group>
        <group group_id="P2">
          <title>Metformin</title>
          <description>Metformin 500 mg pills over-encapsulated up to 4 pills daily as tolerated</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Matching over-encapsulated placebo pills</description>
        </group>
        <group group_id="B2">
          <title>Metformin</title>
          <description>Metformin 500 mg pills over-encapsulated up to 4 pills daily as tolerated</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="71"/>
            <count group_id="B2" value="75"/>
            <count group_id="B3" value="146"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.0" spread="10.3"/>
                    <measurement group_id="B2" value="41.4" spread="11.5"/>
                    <measurement group_id="B3" value="43.2" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Difference in Body Weight Change Between Participants Assigned to Metformin and Participants Assigned to Placebo</title>
        <description>Mean difference in body weight change between participants assigned to metformin and participants assigned to placebo from baseline to last study visit (up to 16 weeks)</description>
        <time_frame>Measured at the last study visit</time_frame>
        <population>Evaluable population that took assigned study treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching over-encapsulated placebo pills</description>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
            <description>Metformin 500 mg pills over-encapsulated up to 4 pills daily as tolerated</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Difference in Body Weight Change Between Participants Assigned to Metformin and Participants Assigned to Placebo</title>
          <description>Mean difference in body weight change between participants assigned to metformin and participants assigned to placebo from baseline to last study visit (up to 16 weeks)</description>
          <population>Evaluable population that took assigned study treatment</population>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" lower_limit="-2.0" upper_limit="-0.0"/>
                    <measurement group_id="O2" value="-3.0" lower_limit="-4.0" upper_limit="-2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Cholesterol From Baseline to 16 Weeks</title>
        <description>Total cholesterol</description>
        <time_frame>16 weeks</time_frame>
        <population>randomized participants who took assigned treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Cholesterol From Baseline to 16 Weeks</title>
          <description>Total cholesterol</description>
          <population>randomized participants who took assigned treatment</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="-6.5" upper_limit="6.9"/>
                    <measurement group_id="O2" value="-8.9" lower_limit="-15.6" upper_limit="-2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HDL Cholesterol From Baseline to 16 Weeks</title>
        <description>high-density lipoprotein</description>
        <time_frame>16 weeks</time_frame>
        <population>randomized participants who took assigned treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
          </group>
        </group_list>
        <measure>
          <title>Change in HDL Cholesterol From Baseline to 16 Weeks</title>
          <description>high-density lipoprotein</description>
          <population>randomized participants who took assigned treatment</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" lower_limit="-2.3" upper_limit="1.4"/>
                    <measurement group_id="O2" value="-0.6" lower_limit="-2.4" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in LDL Cholesterol From Baseline to 16 Weeks</title>
        <description>low-density lipoprotein</description>
        <time_frame>16 weeks</time_frame>
        <population>participants who took assigned treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
          </group>
        </group_list>
        <measure>
          <title>Change in LDL Cholesterol From Baseline to 16 Weeks</title>
          <description>low-density lipoprotein</description>
          <population>participants who took assigned treatment</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" lower_limit="-7.7" upper_limit="3.7"/>
                    <measurement group_id="O2" value="-7.1" lower_limit="-12.6" upper_limit="-1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Triglycerides From Baseline to 16 Weeks</title>
        <description>serum triglycerides</description>
        <time_frame>16 weeks</time_frame>
        <population>participants who took assigned treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Triglycerides From Baseline to 16 Weeks</title>
          <description>serum triglycerides</description>
          <population>participants who took assigned treatment</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2" lower_limit="-0.3" upper_limit="26.7"/>
                    <measurement group_id="O2" value="-7.0" lower_limit="-20.4" upper_limit="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Glucose From Baseline to 16 Weeks</title>
        <description>fasting blood glucose</description>
        <time_frame>16 weeks</time_frame>
        <population>participants who took assigned treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Glucose From Baseline to 16 Weeks</title>
          <description>fasting blood glucose</description>
          <population>participants who took assigned treatment</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" lower_limit="-4.3" upper_limit="1.2"/>
                    <measurement group_id="O2" value="-2.3" lower_limit="-5.0" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Insulin From Baseline to 16 Weeks</title>
        <description>Fasting insulin</description>
        <time_frame>16 weeks</time_frame>
        <population>participants who took assigned treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Insulin From Baseline to 16 Weeks</title>
          <description>Fasting insulin</description>
          <population>participants who took assigned treatment</population>
          <units>mU/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" lower_limit="-1.7" upper_limit="12.6"/>
                    <measurement group_id="O2" value="1.6" lower_limit="-5.5" upper_limit="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hemoglobin A1c From Baseline to 16 Weeks</title>
        <description>glycosylated hemoglobin</description>
        <time_frame>16 weeks</time_frame>
        <population>participants who took assigned treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Hemoglobin A1c From Baseline to 16 Weeks</title>
          <description>glycosylated hemoglobin</description>
          <population>participants who took assigned treatment</population>
          <units>percent</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" lower_limit="-0.04" upper_limit="0.06"/>
                    <measurement group_id="O2" value="-0.06" lower_limit="-0.11" upper_limit="-0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Matching over-encapsulated placebo pills</description>
        </group>
        <group group_id="E2">
          <title>Metformin</title>
          <description>Metformin 500 mg pills over-encapsulated up to 4 pills daily as tolerated</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>rule-out myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>elective knee-surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>rule-out seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidality</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Exacerbation of schizophrenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="71"/>
                <counts group_id="E2" events="25" subjects_affected="25" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="71"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>abdominal discomfort</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="71"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle pain</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="71"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>weakness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="71"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="71"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Changes over periods of more than 16 weeks are unknown.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Scott Stroup</name_or_title>
      <organization>Columbia University</organization>
      <phone>212-543-5676</phone>
      <email>stroups@nyspi.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

